The progress of the APPROACH study represents a critical operational milestone for the company, as late-stage psychiatric trials frequently face delays due to recruitment challenges. By moving toward the final phase of enrollment, Helus Pharma aims to substantiate earlier findings that suggested potential improvements in neuroplasticity. Previous Phase 2 data indicated a significant reduction in Montgomery-Asberg Depression Rating Scale scores, though these results remain preliminary and require confirmation in the ongoing larger-scale trial.
In section Releases
Helus Pharma Advances Depression Drug Trial Toward 2026 Readout
Helus Pharma has surpassed 86% enrollment in its Phase 3 APPROACH trial for HLP003, a candidate designed to treat major depressive disorder. With the study moving toward a topline data release in the fourth quarter of 2026, the company remains focused on validating its novel serotonergic agonist platform under FDA Breakthrough designation.
HLP003 functions as a synthetic molecule intended to activate serotonin pathways, aiming for more durable patient outcomes than traditional antidepressants. The program is currently part of the broader PARADIGM clinical structure, which includes long-term extension studies designed to build a comprehensive efficacy and safety profile. While the FDA has granted Breakthrough Therapy status, this designation accelerates regulatory engagement rather than guaranteeing eventual approval. As the company works toward its 2026 deadline, it faces a competitive landscape where peers like Compass Pathways and Definium Therapeutics are also seeking to establish new standards for depression treatment using similar clinical endpoints.
Comments (0)
No comments yet. Be the first!